Alar Pharmaceuticals Inc. (TPEX:6785)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
198.50
-22.00 (-9.98%)
Mar 2, 2026, 1:30 PM CST
33.22%
Market Cap 14.73B
Revenue (ttm) 1.25M
Net Income (ttm) -29.36M
Shares Out 66.80M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend 0.25 (0.11%)
Ex-Dividend Date Jun 10, 2025
Volume 824,518
Average Volume 233,088
Open 217.00
Previous Close 220.50
Day's Range 198.50 - 217.00
52-Week Range 108.50 - 317.00
Beta 0.19
RSI 24.46
Earnings Date Mar 13, 2026

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan. [Read more]

Sector Healthcare
Founded 2016
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6785
Full Company Profile

Financial Performance

In 2024, Alar Pharmaceuticals's revenue was 5.82 million, a decrease of -98.76% compared to the previous year's 469.27 million. Earnings were 18.17 million, a decrease of -95.25%.

Financial Statements

News

There is no news available yet.